Adventrx Pharmaceuticals, Inc., a biopharmaceutical company focused on developing proprietary product candidates, has entered into a multi-year agreement with Patheon Inc. under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the phase III study of ANX-188 that Adventrx plans to initiate this year.

“This agreement is another step toward initiating the phase III study of ANX-188 in patients with sickle cell disease,” said Brian M Culley, chief executive officer of Adventrx. “Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world's largest pharmaceutical and biotechnology companies. I am confident in their manufacturing expertise, experienced staff and world-class facilities and pleased to partner with them for the manufacture of ANX-188 clinical trial material.”

Patheon is a leading global provider of contract dosage form development and manufacturing services to the pharmaceutical and biotechnology industries.